secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2024-07-02T23:59:59+00:00
Accession:  0001367644-24-000116
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emergent secures $250M+ in U.S. gov't contracts for smallpox, anthrax, botulism meds
--------------------------------------------------------------------------------

- Modification 12 for ACAM2000 smallpox vaccine valued at $99.9M; delivery by Sept 30, 2024.
- Modification 17 for CYFENDUS anthrax vaccine valued at $30.0M for delivery this year.
- Two options totaling $122.9M for VIGIV (smallpox complication) and BAT (botulism antitoxin) into early 2025.
- All awards from ASPR under existing 10-year contracts; reaffirms Emergent as trusted biodefense partner.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764424000116/0001367644-24-000116-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764424000116/ebs-20240628.htm
  HTML page:      https://secwatch.observer/filing/0001367644-24-000116

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer